Given the association between abdominal obesity and reduced GH secretion, however, augmentation of GH may be one effective strategy to address NAFLD/NASH in those with NAFLD who also exhibit obesity or excess abdominal adiposity. The gene discussed is GH1; the disease is metabolic dysfunction-associated steatotic liver disease.